B
ecause of its high prevalence, hypertension is responsible for more atrial fibrillation (AF) than any other risk factors, accounting for 22% of incident AF cases. 1 Not only is the presence of hypertension associated with the development of AF, it also is associated with the progression to more persistent forms of AF. 2 Furthermore, there is evidence that hypertension is an independent predictor for AF recurrence following catheter ablation. 3 The above is of no surprise because both large and small animal studies have clearly demonstrated the adverse effects of hypertension on abnormal atrial remodeling that include slow and heterogenous atrial conduction, increased interstitial fibrosis, and inflammation that result in increased atrial arrhythmogenicity. 4, 5 Similar findings were seen from electroanatomical right atria mapping in chronically treated hypertensive patients with conduction slowing, areas of low-voltage and increased AF vulnerability. 6 It is important to note that these abnormal atrial changes have been shown to be reversible with blood pressure (BP) lowering therapy in a rat study. 7 However, there have been no definitive guidelines for the treatment target when treating high BP in AF individuals. It is in this context that the randomized study by Parkash et al on the effect of aggressive BP control on the recurrence of AF after catheter ablation in this issue of Circulation is a welcome addition to the literature. 8 This prospective multicenter study recruited 184 patients, with hypertension and symptomatic AF refractory to at least 1 antiarrhythmic drug, who were scheduled for catheter ablation. The subjects were randomized to standard or aggressive BP treatment with systolic BP target of 120 mm Hg or 140 mm Hg, respectively. In the aggressive treatment arm, medications were titrated every other week per home measurements using an automated sphygmomanometer for up to 6 months before and 3 months after catheter ablation procedure. The BP lowering strategy consisted of quinapril (to the maximum dose of 40 mg) and followed by stepwise addition of hydrochlorothiazide (12.5 mg), atenolol (50 mg), amlodipine (2.5-10 mg), and terazosin (1 mg), as required. The 2 groups were well matched with the majority being obese white men at a mean age of 60 years old and a relatively low CHADs score (>80% scoring 0 or 1). The aggressive treatment group required significantly more antihypertensive medications (4.6 versus 3.0) and achieved lower systolic BP (123 versus 135 mm Hg) at 6 months although the differences in BP levels appear to be smaller by 12 months. At median follow-up of 14 months, there was no significance difference in the primary outcome of recurrent symptomatic atrial arrhythmia beyond 3 months post ablation (61.4 versus 61.2% in the aggressive versus standard group). Similarly, no differences were seen in the secondary outcomes of any atrial arrhythmias post randomization or 3 months post ablation irrespective of symptoms, recurrent ablation therapy, AF hospitalizations and thromboembolic events except for higher AF-related emergency presentations in the aggressive treatment group (30 versus 17%). The investigators
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Correspondence to: Prashanthan Sanders, Centre for Heart Rhythm Disorders (CHRD), Department of Cardiology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia. E-mail prash. sanders@adelaide.edu.au Key Words: Editorials ◼ atrial fibrillation ◼ diabetes mellitus ◼ high blood pressure ◼ obesity ◼ obstructive sleep apnea also reported on a prespecified subgroup analysis by median age whereby significantly lower systolic BP level was only achieved in the aggressive treatment group versus the standard group in those over 61 years old at 6 months. Along with this, a significantly lower number of those over 61 years old in the aggressive treatment group met the primary outcome than their counterparts in the standard group with a hazard ratio of 0.58. Of note, this study also reported higher incidence of hypotension requiring medication change in the aggressive treatment group (26 versus 0%).
The authors concluded that aggressive targeting of BP for a median duration of 3.5 months prior to catheter ablation and then after had no effect on subsequent arrhythmia outcome despite at the expense of treatment related hypotension. This seemingly neutral outcome is not in keeping with other recent studies whereby aggressive risk factor management was found to improve sinus rhythm maintenance. [9] [10] [11] Notably, aggressive risk factor modification has been used in a randomized clinical trial with additional long-term data presented from prospective observational cohorts in the ARREST-AF Cohort (Aggressive Risk Factor Reduction Study for Atrial Fibrillation) and LEGACY (Long-Term Effect of Goal Directed Weight Management in an Atrial Fibrillation Cohort: A Long-term Follow-Up Study) studies. In these studies undertaken in overweight or obese individuals with AF, in addition to treating BP, risk factor management included: structured and goal-directed weight management through dietary modification aiming for 10% weight loss initially followed by a target body mass index of <27 kg/ m 2 , tailored moderate intensity exercise to improve cardiorespiratory fitness, screening and treating obstructive sleep apnea with continuous positive airways pressure therapy, lipid and glycemic management aiming for low-density lipoprotein (LDL) <2.6 mmol/L and HbA1c (glycated hemoglobin) <6.5%, smoking cessation and alcohol abstinence or reduction to not more than 3 standard drinks per week. [9] [10] [11] In contrast to the results presented in the study by Parkash et al, 8 this comprehensive risk factor modification strategy demonstrated significant improvement arrhythmia free survival over a mean follow-up duration of 42 months in those with initial body mass index of ≥27 kg/m 2 that underwent catheter ablation for symptomatic AF. 10 Of note, significant reverse remodeling in left atrial and left ventricular septal dimensions were seen with improvement in risk factor control following such strategy.
In discussing the neutral results, the authors identified several contributing factors such as a relatively well treated control group (systolic BP of 135 mm Hg) and advanced atrial substrate at the outset that may be irreversible to treatment at 30 months after AF diagnosis. However, several other factors are also worth considering. First, the treatment duration may be too short for reverse remodeling to translate into rhythm outcome.
Second, only a small difference in systolic BP was evident at 12 months between the 2 groups who were mildly hypertensive at baseline. As seen in the renal denervation data, significant benefits were only achieved when treating BP in those with severe resistant hypertension. 12 Third, other coexisting risk factors such as obesity, physical inactivity, alcohol consumption, and sleep apnea were not actively monitored or treated, which might confound the results of aggressive BP treatment alone. Last, there is a possibility of underpowering to detect the beneficial effect of aggressive BP lowering on rhythm outcome.
Nevertheless, the authors ought to be congratulated for the solid attempt in examining an important facet of AF care regarding BP target in those with hypertension. It is important to note that the positive signal from the prespecified subgroup analysis in those over 61 years of age could be underpinned by more significant differences in treated systolic BP level. While the primary outcome of arrhythmia recurrence for the entire cohort appears neutral, it remains likely that aggressive BP lowering may have improved underlying atrial substrate should electroanatomical mapping was undertaken. Additionally, considerations should be given to the concept of assessing and targeting aortic stiffness and central hypertension when managing hypertensive patients with AF given emerging data on their associations with AF. 13, 14 Specifically, aortic stiffness assessed using brachial pulse pressure was found have stronger association with AF development than systolic BP alone in large observational cohort study. 13 In lone AF patients, central aortic stiffness indices derived from radial artery applanation tonometry were found to portend higher AF recurrence following catheter ablation despite similar systolic BP levels.
14 Further studies are therefore needed to provide more definitive guidance on BP targets in AF patients beyond current recommendation of good BP control. 15 With increasing research, the landscape of AF care will continue to evolve with growing understanding of AF pathogenesis to facilitate individualized mechanisticbased therapy. The rising burden of AF demands increasing attention on AF prevention and upstream therapy beyond improved phenotyping of AF patients, novel therapeutics and ablative technologies. The current work by Parkash and colleagues 8 on the theme of aggressive BP control contributes to the present focus on a new paradigm of lifestyle and risk factor modification aiming to improve AF outcomes. It is vital that the risk factor management strategy addresses all the risk factors that are present in an AF individual to maximize the chance of reverse atrial remodeling and sinus rhythm maintenance.
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